Brought to you by 
OncoResponse launched by Theraclone, MD Anderson; initiates Series A; round closes at $22.5mm
22 Sep 2020
Executive Summary
Theraclone Sciences Inc. and the MD Anderson Cancer Center have together spun out a new company, OncoResponse Inc., which will develop antibodies against immuno-oncology targets. The new entity also received $9.5mm in Series A round funding.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- Spin-Off
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
OncoResponse launched by Theraclone, MD Anderson; initiates Series A; round closes at $22.5mm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice